hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
Clinical trial NCT03824691 · UNKNOWN
Trial details
- NCT number
- NCT03824691
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-25
- Primary completion
- 2023-02-01
- Enrollment
- 122
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.